Abstracts tagged "juvenile idiopathic arthritis (JIA)"

Abstract Number: 2773 • 2017 ACR/ARHP Annual Meeting
Severe Juvenile Arthritis Associated with a De Novo Gain-of-Function Germline Mutation in MYD88
Keith A. Sikora¹, Joshua R. Bennett², Laurens Vyncke³, Zuoming Deng⁴, Wanxia Li Tsai², Ewald Pauwels⁵, Gerlinde Layh-Schmitt², April D. Brundidge², Fatemeh Navid², Kristien Zaal⁶, Eric Hanson², Massimo G. Gadina⁷, Louis M. Staudt⁸, Thomas A. Griffin⁹, Jan Tavernier³, Frank Peelman³ and Robert Colbert², ¹Pediatric Translational Research Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ²National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ³Department of Biochemistry, Ghent University, Ghent, Belgium, ⁴Biodata Mining & Discovery, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁵Center for Molecular Modeling, Ghent University, Ghent, Belgium, ⁶Light Imaging Section, Office of Science and Technology, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁷Translational Immunology, Office of Science and Technology, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁸National Cancer Institute, National Institutes of Health, Bethesda, MD, ⁹Levine Children’s Hospital at Carolinas Medical Center, Charlotte, NC
Background/Purpose: Using whole exome sequencing, we discovered a de novo heterozygous germline mutation in MYD88 (myeloid differentiation primary response 88) (c.666T>G, p.S222R) in a child…
Abstract Number: 2275 • 2017 ACR/ARHP Annual Meeting
Factors Related to Sustained Discontinuation of Medications for Well-Controlled JIA in the Childhood Arthritis & Rheumatology Research Alliance Registry
Daniel B. Horton¹, Fenglong Xie², Melissa L. Mannion³, Sarah Ringold⁴, Colleen K. Correll⁵, Anne C. Dennos⁶ and Timothy Beukelman⁷, ¹Rutgers Biomedical and Health Sciences, New Brunswick, NJ, ²Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³Pediatric rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁴Seattle Children's Hospital, Seattle, WA, ⁵Pediatrics, University of Minnesota, Minneapolis, MN, ⁶Duke Clinical Research Institute, Durham, NC, ⁷Pediatrics, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Stopping medications is a priority for many patients with well-controlled JIA, but few factors predict favorable outcomes after discontinuation. We examined factors associated with…
Abstract Number: 2855 • 2017 ACR/ARHP Annual Meeting
Subcutaneous Abatacept in Patients Aged 2–17 Years with Polyarticular Juvenile Idiopathic Arthritis and Inadequate Response to Biologic or Non-Biologic Disease-Modifying Antirheumatic Drugs: Pharmacokinetics, Effectiveness, Safety and Immunogenicity over 2 Years
Hermine I. Brunner¹, N Ruperto², G Vega-Cornejo³, A Berman⁴, Inmaculada Calvo⁵, R Cuttica⁶, F Ávila-Zapata⁷, Michael Henrickson¹, DJ Kingsbury⁸, D Viola⁹, V Keltsev¹⁰, K Minden¹¹, John F. Bohnsack¹², X Li¹³, M Nys¹⁴, R Wong¹³, S Banerjee¹³, Daniel J Lovell¹ and Alberto Martini¹⁵, ¹Cincinnati Children’s Hosp. Medical Center, Cincinnati, OH, ²Istituto G. Gaslini Pediatria II Reumatologia, Genoa, Italy, ³Clinica de Reumatología y Enfermedades Autoinmunes (CREA), Hospital México Americano, Guadalajara Jalisco, Mexico, ⁴Universidad Nacional de Tucuman and Centro Médico Privado de Reumatología, Tucuman, Argentina, ⁵Hospital Univ. La Fe, Valencia, Spain, ⁶Hospital General de Niños Pedro de Elizalde, Buenos Aires, Argentina, ⁷Star Medica Hospital, Yucatán, Mexico, ⁸Randall Children’s Hospital at Legacy Emanuel, Portland, OR, ⁹CAICI Institute, Rosario City, Santa Fe State, Argentina, ¹⁰GBUZ Samara region "Togliatti City Clinical Hospital No.5" Rheumatology Department, Togliatti, Russian Federation, ¹¹German Rheumatism Research Center and Charité University Medicine, Berlin, Germany, ¹²University of Utah School of Medicine, Salt Lake City, UT, ¹³Bristol-Myers Squibb, Princeton, NJ, ¹⁴Bristol-Myers Squibb, Braine-l’Alleud, Belgium, ¹⁵Istituto G. Gaslini Pediatria II Reumatologia and University of Genova, Genoa, Italy
Background/Purpose: IV abatacept (ABA) 10 mg/kg every 4 weeks is well tolerated and effective in reducing the signs and symptoms of polyarticular juvenile idiopathic arthritis…
Abstract Number: 2279 • 2017 ACR/ARHP Annual Meeting
Dynamics of Concomitant Therapy in Children with Juvenile Idiopathic Arthritis Treated with Etanercept
Ekaterina Alexeeva^1,2, Tatiana Dvoryakovskaya^1,2, Victor Gladkikh^3,4, Andrei Moskalev^4,5, Rina Denisova², Ksenia Isaeva², Olga Lomakina², Margarita Soloshenko² and Anna Karaseva², ¹Pediatrics, The Federal State Autonomous Educational Institution of Higher Education The First Moscow State Medical University named after I.M. Sechenov Ministry of Health of the Russian Federation (Sechenov University), Moscow, Russian Federation, ²Reumatology department, Federal State Autonomous Institution"National Scientific and Practical Center of Children's Health"Of the Ministry of Health of the Russian Federation, Moscow, Russian Federation, ³Department of Biostatistics, EOL Labs ltd, Novosibirsk, Rwanda, ⁴Laboratory of Computational Physics, Institute of Computational Mathematics and Mathematical Geophysics SB RAS, Novosibirsk, Russian Federation, ⁵Department of Biostatistics, EOL Labs ltd, Novosibirsk, Russian Federation
Background/Purpose: The effectiveness of target use of biological medications depends on how personalized they are to fit patient’s individual parameters with juvenile idiopathic arthritis (JIA).…
Abstract Number: 2856 • 2017 ACR/ARHP Annual Meeting
Evaluation of a Dosing Regimen for Tocilizumab in Patients Younger Than Two Years of Age with Systemic Juvenile Idiopathic Arthritis
Navita L. Mallalieu¹, Joy Hsu¹, Karen Wang¹, Sunethra Wimalasundera², Wendy Douglass², Chris Wells², Inmaculada Calvo³, Rubén Cuttica⁴, Hans-Iko Huppertz⁵, Rik Joos⁶, Yukiko Kimura⁷, Diana Milojevic⁸, Margalit Rosenkranz⁹, Kenneth Schikler¹⁰, Tamas Constantin¹¹ and Carine Wouters¹², ¹Roche Innovation Center, New York, NY, ²Roche Products, Ltd., Welwyn Garden City, United Kingdom, ³Hospital Universitario y Politécnico La Fe, Valencia, Spain, ⁴Hospital Gral de Niños Pedro Elizalde, Buenos Aires, Argentina, ⁵Professor Hess Children's Hospital, Bremen, Germany, ⁶ZNA, Antwerp, and UZ, Gent, Belgium, ⁷Hackensack University Medical Center, Hackensack, NJ, ⁸Tufts Medical Center, Boston, MA, ⁹Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA, ¹⁰University of Louisville Medical School, Louisville, KY, ¹¹Semmelweis University, Budapest, Hungary, ¹²University Hospital Gasthuisberg, Leuven, Belgium
Background/Purpose: Tocilizumab (TCZ) is approved for the treatment of systemic juvenile idiopathic arthritis (sJIA) based on clinical trials in patients ≥2 years of age. This…
Abstract Number: 2280 • 2017 ACR/ARHP Annual Meeting
Effectiveness of Switching to Adalimumab As the Second- and Third-Line Biological Drug in Patients with Juvenile Idiopathic Arthritis
Ekaterina Alexeeva¹, Tatiana Dvoryakovskaya², Victor Gladkikh^3,4, Andrei Moskalev^4,5, Rina Denisova¹, Ksenia Isaeva¹, Olga Lomakina¹, Margarita Soloshenko¹ and Anna Karaseva¹, ¹Reumatology department, Federal State Autonomous Institution"National Scientific and Practical Center of Children's Health"Of the Ministry of Health of the Russian Federation, Moscow, Russian Federation, ²Pediatrics, The Federal State Autonomous Educational Institution of Higher Education The First Moscow State Medical University named after I.M. Sechenov Ministry of Health of the Russian Federation (Sechenov University), Moscow, Russian Federation, ³Department of Biostatistics, EOL Labs ltd, Novosibirsk, Rwanda, ⁴Laboratory of Computational Physics, Institute of Computational Mathematics and Mathematical Geophysics SB RAS, Novosibirsk, Russian Federation, ⁵Department of Biostatistics, EOL Labs ltd, Novosibirsk, Russian Federation
Background/Purpose: The range of biological drugs currently used in JIA therapy includes not only anti-TNF but also other varieties. However, despite the high effectiveness and…
Abstract Number: 2857 • 2017 ACR/ARHP Annual Meeting
Short and Long-Term Follow-up of Tocilizumab for Severe Juvenile Idiopathic Arthritis-Associated Uveitis
Nuria Vegas-Revenga¹, Vanesa Calvo-Río¹, Montserrat Santos-Gómez², Inmaculada Calvo³, Mº Isabel González- Fernández³, Berta López- Montesinos³, Marina Mesquida⁴, Alfredo Adan⁴, M. Victoria Hernández⁴, Olga Maiz⁵, Antonio Atanes⁶, Beatriz Bravo⁷, Consuelo Modesto⁸, Gisela Díaz-Cordovés⁹, Natalia Palmou-Fontana¹, Javier Loricera¹, MC Gonzalez-Vela¹⁰, Rosalia Demetrio¹¹, Carlos Fernández-Díaz¹, Lucia C. Domínguez-Casas¹, José Luis Martín-Varillas¹, Belén Atienza-Mateo¹, Jose L. Hernández¹², Miguel Angel González-Gay¹ and Ricardo Blanco¹, ¹Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ²Rheumatology, Hospital de Sierrallana. Torrelavega. Spain, Torrelavega, Spain, ³Rheumatology, Hospital Universitario i Politecnico La Fe. Valencia. Spain, Valencia, Spain, ⁴Hospital Clinic. Barcelona. Spain, Barcelona, Spain, ⁵Hospital Donostia. Spain, San Sebastian, Spain, ⁶Rheumatology, Complejo Hospitalario Universitario A Coruña (CHUAC). Spain, A Coruna, Spain, ⁷Rheumatology, HU Virgen de las Nieves. Granada. Spain, Granada, Spain, ⁸Hospital Universitari Vall d'Hebron. Barcelona. Spain, Barcenola, Spain, ⁹Rheumatology, Hospital Regional Universitario de Málaga. Spain, Málaga, Spain, ¹⁰Pathology Anatomy, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ¹¹Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ¹²Internal Medicine, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain
Background/Purpose: Our objective was to assess the efficacy of tocilizumab (TCZ) at short and long term follow-up for severe juvenile idiopathic arthritis-associated uveitis.Methods: A Multicentre…
Abstract Number: 2281 • 2017 ACR/ARHP Annual Meeting
Patterns of Medication Use in Non-Systemic Polyarthritis: Data from the Childhood Arthritis and Rheumatology Research Alliance Patient Registry
Sarah Ringold¹, Fenglong Xie², Daniel B. Horton³, Melissa L. Mannion⁴, Colleen K. Correll⁵, Anne C. Dennos⁶ and Timothy Beukelman⁷, ¹Seattle Children's Hospital, Seattle, WA, ²Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³Pediatrics, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, ⁴Pediatric rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁵Pediatrics, University of Minnesota, Minneapolis, MN, ⁶Duke Clinical Research Institute, Durham, NC, ⁷Pediatric Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: The Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry began enrolling children with juvenile idiopathic arthritis (JIA) in July 2015. The large number of…
Abstract Number: 2858 • 2017 ACR/ARHP Annual Meeting
Validation of Biomarkers to Predict Flare in Polyarticular JIA upon Stopping Anti-TNF Therapy
Daniel J Lovell¹, Sarah Ringold² and P. Scott Eastman³, ¹PRCSG, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ²Seattle Children's Hospital, Seattle, WA, ³Senior Director, New Product Development, Crescendo Bioscience, South San Francisco, CA
Background/Purpose: More than 40% of children with polyarticular forms of Juvenile Idiopathic Arthritis (JIA) experience clinical inactive disease on medication (CR). No clinical variable or…
Abstract Number: 2286 • 2017 ACR/ARHP Annual Meeting
Determinants of Anti-Tumor Necrosis Factor Drug Use in Juvenile Spondyloarthropathy and Impact on Clinical Disease Outcomes
Melissa Oliver¹, Julia F Simard², Dana Gerstbacher³, Tzielan Lee⁴ and Christy Sandborg⁵, ¹Pediatric Rheumatology, Stanford University, Department of Pediatric Rheumatology, Palo Alto, CA, ²Division of Epidemiology, Health Research and Policy Department, Stanford School of Medicine, Stanford, CA, ³Stanford University, Palo Alto, CA, ⁴Pediatric Rheumatology, Stanford University, Palo Alto, CA, ⁵Pediatric Rheumatology PTD, Stanford Medical Center, Palo Alto, CA
Background/Purpose: Patients with juvenile spondyloarthropathy (JSpA) have lower clinical remission rates, report higher pain scores, worse functioning and lower quality of life compared to other…
Abstract Number: 2952 • 2017 ACR/ARHP Annual Meeting
A Randomized Controlled Trial (RCT) of an Internet-Based Self-Management Program for Adolescents with Juvenile Idiopathic Arthritis (JIA)
Jennifer N. Stinson¹, Sarah Campillo², Tania Cellucci³, Paul Dancey⁴, Ciarán M. Duffy⁵, Janet Ellsworth⁶, Brian M. Feldman⁷, Adam Huber⁸, Nicole Johnson⁹, Patrick McGrath⁸, Alan Rosenberg¹⁰, Natalie J. Shiff¹¹, Lynn R. Spiegel¹², Shirley M.L. Tse¹³, Lori Tucker¹⁴, J. Charles Victor¹⁵ and Stephanie Luca¹⁶, ¹Anesthesia and Pain Medicine, The Hospital for Sick Children, Toronto, ON, Canada, ²Montreal Children's Hospital, Montreal, QC, Canada, ³McMaster University, hamilton, ON, Canada, ⁴Pediatrics, Janeway Children's Hospital, St. John's, NL, Canada, ⁵Children's Hospital of Eastern Ontario and University of Ottawa, Ottawa, ON, Canada, ⁶University of Alberta, Edmonton, AB, Canada, ⁷Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ⁸IWK Health Centre, Halifax, NS, Canada, ⁹Alberta Children's Hospital, University of Calgary, Calgary, AB, Canada, ¹⁰Pediatrics, University of Saskatchewan, Saskatoon, SK, Canada, ¹¹University of Florida, Gainesville, FL, ¹²Rheumatology/Pediatrics, The Hospital for Sick Children, Toronto, ON, Canada, ¹³Rheumatology, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada, ¹⁴BC Children's Hospital, Vancouver, BC, Canada, ¹⁵University of Toronto, Toronto, ON, Canada, ¹⁶The Hospital for Sick Children, Toronto, ON, Canada
Background/Purpose: Juvenile Idiopathic Arthritis (JIA) is a common chronic childhood illness associated with negative impact on health-related quality of life (HRQL). As teens mature, they…
Abstract Number: 2293 • 2017 ACR/ARHP Annual Meeting
Can We Predict Achievement of Clinically Inactive Disease and Sustained Remission in Children with Juvenile Idiopathic Arthritis?
Stephanie Shoop-Worrall¹, Suzanne M Verstappen², Janet E. McDonagh³, Wendy Thomson⁴ and Kimme L. Hyrich¹, ¹The University of Manchester, Arthritis Research UK Centre for Epidemiology, Manchester, United Kingdom, ²Centre for Musculoskeletal Research, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, The University of Manchester, Arthritis Research UK Centre for Epidemiology, Manchester, United Kingdom, ³Faculty of Medical and Human Sciences, Centre for MSK Research, Manchester, United Kingdom, ⁴Arthritis Research UK Centre for Genetics and Genomics,The University of Manchester, Manchester, United Kingdom
Background/Purpose: Identifying predictors for clinically inactive disease (CID) and sustained remission would allow rapid escalation of therapies for children less likely to achieve these states.…
Abstract Number: 2994 • 2017 ACR/ARHP Annual Meeting
Improving Outcomes Using a Treat to Target Approach and Clinical Decision Support in Polyarticular Juvenile Idiopathic Arthritis
Lisa Buckley¹, Eileen Ware², Genna Kreher², Lisa Wiater¹, Jay Mehta¹ and Jon (Sandy) Burnham¹, ¹Pediatric Rheumatology, Children's Hospital of Philadelphia, Philadelphia, PA, ²Office of Clinical Quality Improvement, Children's Hospital of Philadelphia, Philadelphia, PA
Background/Purpose: Polyarticular juvenile idiopathic arthritis (Poly-JIA) causes pain, functional disability, and joint damage. Variation in Poly-JIA clinical assessment and treatment likely has a negative…
Abstract Number: 2294 • 2017 ACR/ARHP Annual Meeting
Utilizing the Pediatric Rheumatology Care and Outcomes Improvement Network to Assess Practice Pattern Variation in Juvenile Idiopathic Arthritis
Emily A. Smitherman¹, Janalee Taylor², Esi M. Morgan¹ and C. April Bingham³, ¹Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³Pediatrics, Penn State College of Medicine, Hershey, PA
Background/Purpose: Despite modern treatment options for patients with juvenile idiopathic arthritis (JIA), rates of clinical inactive disease (CID) remain low. The Pediatric Rheumatology Care and…
Abstract Number: 135 • 2017 Pediatric Rheumatology Symposium
Epigenetic Profiling Of Juvenile Idiopathic Arthritis (JIA) Synovial Fluid Monocytes Points Towards a Role For Monocytes In Bone Damage
Janneke Peeters¹, Arjan Boltjes^2,3, Stephin Vervoort⁴, Paul Coffer¹, Bas Vastert^2,5, Femke van Wijk^2,3, Michal Mokry³, Teun de Vries^6,7 and Jorg van Loosdregt³, ¹Center for Molecular Medicine and Regenerative Medicine Center Utrecht, University Medical Center Utrecht, Utrecht, Netherlands, ²Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ³Division of Pediatrics, University Medical Center Utrecht, Utrecht, Netherlands, ⁴Peter MacCallum Cancer Centre, Melbourne, Australia, ⁵Division of Pediatric Rheumatology, University Medical Center Utrecht, Utrecht, Netherlands, ⁶Department of Oral Cell Biology and Functional Anatomy, Academic Centre for Dentistry Amsterdam, Amsterdam, Netherlands, ⁷Department of Periodontology, Academic Centre for Dentistry Amsterdam, Amsterdam, Netherlands
Background/Purpose: Juvenile Idiopathic Arthritis (JIA) is a multifactorial autoimmune disease characterized by the accumulation of various immune cells, including monocytes, in the joint synovial fluid…

« Previous Page
1
…
7
8
9
10
11
…
19
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].